Research progress of anti-vascular endothelial growth factor receptor 2 drugs in the treatment of retinal neovascularization disease
10.3760/cma.j.cn511434-20201028-00516
- VernacularTitle:抗血管内皮生长因子受体2药物在视网膜新生血管疾病治疗中的研究进展
- Author:
Mingliang ZHANG
1
;
Songyang YANG
;
Lanlan HU
;
Xiaorong LI
Author Information
1. 天津医科大学眼科医院、眼视光学院、眼科研究所 国家眼耳鼻喉疾病临床医学研究中心天津市分中心 天津市视网膜功能与疾病重点实验室 300384
- Keywords:
Receptors, vascular endothelial growth factor;
Retinal neovascularization;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2021;37(7):562-566
- CountryChina
- Language:Chinese
-
Abstract:
Neovascularization is a characteristic manifestation of a variety of retinal diseases. Vascular endothelial growth factor (VEGF) mainly regulates the proliferation and migration of endothelial cells. VEGF receptor 2 (VEGFR2) is the main receptor to mediate this effect. The activation of downstream signals requires the binding of VEGF and VEGFR2, followed by receptor dimerization and autophosphorylation. Blocking this process and inhibiting neovascularization is very attractive treatment ideas. Monoclonal antibodies and fusion protein drugs currently used in ophthalmology can bind free VEGF. In addition, there are also macromolecular antibodies binding VEGFR2 and small molecule tyrosine kinase inhibitors, which is expected to further expand into the field of ophthalmology. Although anti-VEGFR2 therapy is a revolutionary method to inhibit neovascularization, there are no sufficient clinical evidences at present. In-depth understanding of the application status and progress of anti-VEGFR2 in the treatment of retinal neovascular diseases has important clinical significance.
